{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-113241","form_type":"8-K","ticker":null,"cik":"0001693011","company_name":"Inozyme Pharma, Inc.","filed_at":"2024-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.254031+00:00","generated_at":"2026-05-30T19:17:25.917600+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Inozyme Pharma appoints Erik Harris as Class II director effective October 3, 2024","bullets":["Erik Harris, Chief Commercial Officer and EVP at Ultragenyx, appointed to Inozyme's Board as Class II director.","Director compensation: $40,000 annual cash retainer, initial option for 56,000 shares (3-year vest), annual option for 28,000 shares.","Mr. Harris has over 20 years of biopharma commercial experience including roles at InterMune, Genentech, and Bristol-Myers Squibb.","Standard indemnification agreement entered into; no family relationships or transactions with Inozyme officers require disclosure."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-113241","json":"https://secwatch.observer/filing/0000950170-24-113241.json","markdown":"https://secwatch.observer/filing/0000950170-24-113241.md","text":"https://secwatch.observer/filing/0000950170-24-113241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024113241/0000950170-24-113241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024113241/inzy-20241003.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T19:17:25.917600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e52f405cc","claim":"Erik Harris was appointed as Director at Inozyme Pharma, Inc..","evidence_excerpt":"appointed Erik Harris as a director of the Company, effective October 3, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024113241/0000950170-24-113241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}